Abstract: In one embodiment of the present disclosure a haptic actuator is disclosed. The haptic actuator includes a housing, a movable mass, and a pivot assembly attaching the movable mass to the housing. The pivot assembly defines a pivot axis, and the movable mass has a mass center offset from the pivot axis along a lever arm extending perpendicular to the pivot axis. The haptic actuator includes a spring extending between the movable mass and the housing. The spring stores and releases energy received from movement of the movable mass. The spring prevents full rotation of the movable mass about the pivot axis. The haptic actuator includes an electric coil attached to the movable mass. The electric coil intersects the lever arm. The haptic actuator includes at least one magnet attached to the housing. The magnet is at least partially aligned with the electric coil. The movable mass moves with respect to the at least one magnet when a signal is applied to the coil.

Abstract: The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.

Abstract: The present invention is directed to a practical process for the preparation of an enamide (II) by palladium catalyzed coupling of a primary amide (IV) with a compound of structural formula (III), as shown below: As well as to crystalline forms of a compound produced by this process, in particular, an anhydrous crystal form, Form B, and crystalline solvates falling into three patterns, Type 1, Type 2, and Type 3, and crystalline intermediate compounds produced in the process. Still further, the present invention relates to the stereoselective reduction of the tetrasubstituted enamide (II) to the corresponding amide (I).

Abstract: The present invention is directed to a practical process for the preparation of an enamide (II) by palladium catalyzed coupling of a primary amide (IV) with a compound of structural formula (III), as shown below: As well as to crystalline forms of a compound produced by this process, in particular, an anhydrous crystal form, Form B, and crystalline solvates falling into three patterns, Type 1, Type 2, and Type 3, and crystalline intermediate compounds produced in the process. Still further, the present invention relates to the stereoselective reduction of the tetrasubstituted enamide (II) to the corresponding amide (I).

Abstract: This application is directed to a novel polymorph of a hydroisoindoline tachykinin receptor antagonist having the following structural formula A.

Abstract: The present invention relates to a process for producing crystalline N-[1-((3R)-1?-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-6-chloro-5-methyl-2,3-dihydrospiro[indene-1,4?-piperidine]-3-yl)-1-methylethyl]acetamide, and novel salts, solvates, hydrates and polymorphs thereof.

Abstract: The present invention is directed to a practical process for the preparation of an enamide (II) by palladium catalyzed coupling of a primary amide (IV) with a compound of structural formula (III), as shown below: As well as to crystalline forms of a compound produced by this process, in particular, an anhydrous crystal form, Form B, and crystalline solvates falling into three patterns, Type 1, Type 2, and Type 3, and crystalline intermediate compounds produced in the process. Still further, the present invention relates to the stereoselective reduction of the tetrasubstituted enamide (II) to the corresponding amide (I).